Our Team

Meet The StaffOur Team

Our Management

Dr Jonathan Hopper
Chief Executive Officer and Founder

Jonathan Hopper is founder and CEO of OMass Therapeutics. Jonathan completed his PhD in native mass spectrometry under the supervision of Prof. Neil Oldham and moved to the University of Oxford to develop native mass spectrometry approaches for studying membrane proteins with Professor Dame Carol Robinson. His research was focussed on developing technologies which enable or improve the structural/functional information obtained on challenging membrane protein assemblies and drug targets. He founded OMass with the intention of applying these technologies to pharmaceutical research. He led the company through its seed funding and recent series A financing rounds, allowing OMass to now develop its own drug discovery programmes in-house.

Dr Ali Jazayeri
Chief Scientific Officer

Ali Jazayeri joined OMass Therapeutics in October 2018. He was previously Chief Technology Officer of Heptares Therapeutics, a company he joined in 2007 as one of the first scientists and was involved in the transfer of the GPCR stabilisation technology from the MRC Laboratory of Molecular Biology to Heptares. Following successful implementation and industrialisation of the original technology, he led the development of novel methodologies that significantly increased the efficiency and reach of the technology and resulted in the generation of novel IP. In addition, he was one of the key members of the executive sub-team that lead the acquisition of G7 therapeutics, spin out company from University of Zurich and went on to lead the further development  and integration of their technology as part of the Heptares Zurich management team. Prior to Heptares, Ali worked as a post-doctoral scientist in Clare Hall Laboratories (a Cancer Research UK institute) and Kudos Pharmaceuticals (later acquired by AstraZeneca) where he carried out research on the role of cell cycle checkpoint kinases in DNA damage response pathways. He has a BSc in Genetics from University of Manchester and obtained his PhD in molecular biology with Prof Steve Jackson at the Gurdon Institute from University of Cambridge.

Dr Hsin Loke
Vice President, Head of Finance and Strategy

Hsin Loke joined OMass Therapeutics in September 2018 as Vice President, Head of Finance and Strategy. Previously she spent 16 years at GSK in a variety of leadership roles; most recently leading Finance, Strategy and Operations for the Company’s Rare Diseases Unit, which developed and commercialised a portfolio of innovative medicines, including gene therapies. Prior to this, Hsin led Strategy and Operations for GSK’s biotechnology company, and has held roles within an internal consulting group, commercial finance and internal audit. Hsin qualified as a Chartered Accountant with PwC, and completed her BA (Hons) in Biological Sciences and D.Phil. in genetics and immunology at Oxford University.

Dr Giles Brown
Vice President, Medicinal Chemistry

Giles Brown joined OMass Therapeutics as Vice President, Medicinal Chemistry in October 2018 from Heptares Therapeutics. He joined Heptares in 2010 to help develop their structural biology platform as a new approach to structure-based drug design and lead identification for GPCRs. He was promoted to Director of Chemistry in 2015 and Head of Medicinal Chemistry in early 2018. Prior to that he worked for Cambridge BioTechnology (which was acquired by BioVitrum in 2005) as a Medicinal Chemistry Team Leader to help establish the chemistry team and advance the internal pipeline. Previously he worked for Evotec OAI, as a Senior Scientist, a role he took on after completing a two-year postdoctoral position at the University of Pennsylvania in synthetic chemistry. Giles obtained a BSc and PhD in organic chemistry from the University of Bristol and an MBA from Henley Business School at the University of Reading, he is a Fellow of the Royal Society of Chemistry.

Dr Idlir Liko
Director of Technology and Founder

Idlir Liko is currently the founder and Technology Director of OMass Therapeutics. He received a Master’s Degree from ETH Zurich in 2012 and DPhil from the University of Oxford in 2015, supervised by Prof. Dame Carol Robinson where he focused on the effect ligands and PTMs have on structure and stability of membrane proteins. His work was been featured in many high-impact publications. He has a wealth of experience in structural MS working in close collaboration with biotech and pharmaceutical companies. In 2016, he co-founded the company and has played a key role in transferring our technology from academia to industry.

Dr Hsin Yung (Jason) Yen
Director of Biology and Founder

Hsin-Yung (Jason) Yen is the Director of Biology and founder of OMass Therapeutics. After obtaining his PhD degree in glycobiology with Prof Chi-Huey Wong he became a post-doctoral scientist in Professor Dame Carol Robinson’s research group at the University of Oxford. Following his success in GPCR analysis with state-of-the-art mass spectrometry, he recorded the first mass spectrum of a folded GPCR with drug binding maintained. He invented a mass spectrometry platform that reports on compound efficacy on G proteins-/arrestins – coupling with receptors. Now he is leading the scientific team dedicated to GPCR drug discovery.

Our Board of Directors

Dr Jonathan Hopper
Chief Executive Officer and Founder

Jonathan Hopper is founder and CEO of OMass Therapeutics. Jonathan completed his PhD in native mass spectrometry under the supervision of Prof. Neil Oldham and moved to the University of Oxford to develop native mass spectrometry approaches for studying membrane proteins with Professor Dame Carol Robinson. His research was focussed on developing technologies which enable or improve the structural/functional information obtained on challenging membrane protein assemblies and drug targets. He founded OMass with the intention of applying these technologies to pharmaceutical research. He led the company through its seed funding and recent series A financing rounds, allowing OMass to now develop its own drug discovery programmes in-house.

Dr Edward Hodgkin
Executive Chairman

Edward Hodgkin is Executive Chairman of OMass Therapeutics. He is a Partner at Syncona Investment Management Ltd. and was previously a Director of Syncona’s portfolio company, Autolus Therapeutics Ltd. (NASDAQ: AUTL); having served as its first Chief Executive Officer. Prior to Syncona, Ed was Chief Executive Officer of Biotica Technology Ltd. (Cambridge, UK), President & Chief Business Officer of BrainCells Inc. (San Diego, CA) and Vice President, Business Development & Marketing at Tripos (St. Louis, MO). He is also a former chairman of the BioIndustry Association, the UK’s trade body for biotechnology companies. Ed holds an MA and DPhil in Chemistry from the University of Oxford.

Professor Dame Carol Robinson
Founder and Scientific Advisor

Carol is founder of OMass Therapeutics and is a is a non-executive Director and an advisor to the Company. She was appointed Dame Commander of the Order of the British Empire (DBE) in the 2013 New Year Honours for services to science and industry. She is recognised for using mass spectrometry to further research into the 3D structure of proteins and their complexes. Carol’s graduate education was completed whilst working full-time in industry. In 2001 she became the first female Professor in Chemistry at the University of Cambridge, and in 2009 went to the University of Oxford to become the Chair of Dr. Lee’s Professor of Chemistry; a title she still holds. She also holds eight honorary doctorates/degrees, was elected as a Foreign Associate of the US National Academy of Sciences in 2017 and she is the current President of the Royal Society of Chemistry.

Dr Magdalena Jonikas
Non-executive Director

Magdalena is a non-executive Director of OMass Therapeutics. She is a partner of Syncona Investment Management Ltd and previously was an Associate Partner at McKinsey & Company where she specialised in pharmaceuticals Research & Development, portfolio management and Business Development and Licensing. Magdalena holds a PhD in Bioengineering from Stanford University and was a postdoctoral fellow in Harvard Medical School’s Computational Health Informatics Programme.

Lachlan MacKinnon
Non-executive Director

Lachlan MacKinnon is a non-executive Director of OMass Therapeutics and a Principal at Oxford Sciences Innovation (OSI); an investment company formed to turn Oxford’s world beating science in world changing companies. He originally made a seed investment into OMass in 2016 and also represents OSI on the boards of Oxford Nanoimaging, Spybiotech and Opsydia. He studied Chemistry at the University of Oxford.

Dr Martin Murphy
Observer

Martin Murphy is Chief Executive Officer of Syncona Investment Management Ltd and was co-founder of Syncona. Previously, he was a partner at MVM Life Science Partners LLP, a venture capital company focused on life science and healthcare, where he led their European operations and was closely involved in investments including PregLem SA, Momenta Pharmaceuticals, Inc, Healthcare Brands International and Heptares Therapeutics Ltd. Martin has held roles with 3i Group plc and McKinsey & Company. He has a PhD in Biochemistry from the University of Cambridge.

Paul Ashley
Observer

Paul is the Head of Licensing and Ventures at Oxford University Innovation (OUI). OUI works hard to bring Oxford’s best ideas to bear for societal and economic benefit. We support University researchers who wish to commercialise their IP, assisting with licensing and spinout formation, and liaising with technology seekers, investors, and other external parties. Each year OUI sees around 400 ideas come from the full breadth of research activities at the University and Hospitals. Named Technology Transfer Office of the year, OUI produced 25 new companies in 2017. With a research background in Neurophysiology, Paul joined OUI in 2011 following roles in both early-stage spin-outs and large pharmaceutical companies. Paul has helped to commercialise early stage science throughout his career, launching companies and licensing technologies in a broad range of disciplines including drug development, med-tech, genomics, biomarkers and diagnostics and digital health.